Pulse Biosciences Stock Investor Sentiment

PLSE Stock  USD 18.55  0.60  3.13%   
About 56% of all Pulse Biosciences' shareholders are looking to take a long position. The analysis of overall sentiment of trading Pulse Biosciences stock suggests that some investors are interested at this time. The current market sentiment, together with Pulse Biosciences' historical and current headlines, can help investors time the market. In addition, many technical investors use Pulse Biosciences stock news signals to limit their universe of possible portfolio assets.
  

Pulse Biosciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Pulse Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at businesswire.com         
Pulse Biosciences Schedules Fourth Quarter Full Year 2023 Financial Results Conference Call for Marc...
businesswire News
over six months ago at news.google.com         
Pulse Biosciences Shares Gap Up to 9.64 - Defense World
Google News at Macroaxis
over six months ago at massdevice.com         
FDA clears pulsed field ablation electrode tech from Pulse Biosciences
news
over six months ago at businesswire.com         
Pulse Biosciences Announces FDA 510 Clearance for its CellFX nsPFA Percutaneous Electrode System
businesswire News
over six months ago at investing.com         
FDA clears Pulse Biosciences soft tissue ablation system
Investing News at Macroaxis
over six months ago at businesswire.com         
Pulse Biosciences Announces FDA 510 Clearance for its CellFX nsPFA Percutaneous Electrode System
businesswire News
over six months ago at finance.yahoo.com         
Pulse Biosciences Announces FDA 510 Clearance for its CellFX nsPFA Percutaneous Electrode System
Yahoo News
over six months ago at news.google.com         
Pulse Biosciences Inc Banking On FDA Approval - Insider Financial
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Pulse Biosciences Trading 8.1 percent Higher
news
over six months ago at simplywall.st         
Great week for Pulse Biosciences, Inc. insiders who have 70 percent stake and they havent stopped bu...
Simply Wall St News at Macroaxis
over six months ago at finance.yahoo.com         
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in th...
Yahoo News
over six months ago at businesswire.com         
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in th...
businesswire News
over six months ago at businesswire.com         
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in th...
businesswire News
over six months ago at news.google.com         
PLSE Stock Quote Price and Forecast - CNN
Google News at Macroaxis
over six months ago at news.google.com         
Long Term Trading Analysis for - Stock Traders Daily
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Pulse Biosciences that are available to investors today. That information is available publicly through Pulse media outlets and privately through word of mouth or via Pulse internal channels. However, regardless of the origin, that massive amount of Pulse data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pulse Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pulse Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pulse Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pulse Biosciences alpha.

Pulse Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results
10/30/2024
2
Pulse Biosciences Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid ...
10/31/2024
3
Acquisition by Zanganeh Mahkam of 200000 shares of Pulse Biosciences at 15.65 subject to Rule 16b-3
11/05/2024
4
Pulse Biosciences, Inc.s largest shareholder, Top Key Executive Robert Duggan sees holdings value fall by 4.8 percent following recent drop
11/15/2024
5
Pulse Biosciences announces CEO departure and interim leadership
12/06/2024
6
Acquisition by Robert Duggan of 6054 shares of Pulse Biosciences at 16.74 subject to Rule 16b-3
12/11/2024
7
Pulse Biosciences Trading Down 5.4 percent Should You Sell
12/12/2024
8
Acquisition by Robert Duggan of 55256 shares of Pulse Biosciences at 17.18 subject to Rule 16b-3
12/13/2024
9
Robert Duggan Spends US972k On Pulse Biosciences Stock
12/16/2024
10
Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery
12/17/2024
11
Disposition of 24656 shares by Robert Duggan of Pulse Biosciences at 11.0 subject to Rule 16b-3
12/18/2024
12
Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants
12/19/2024

Complementary Tools for Pulse Stock analysis

When running Pulse Biosciences' price analysis, check to measure Pulse Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulse Biosciences is operating at the current time. Most of Pulse Biosciences' value examination focuses on studying past and present price action to predict the probability of Pulse Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulse Biosciences' price. Additionally, you may evaluate how the addition of Pulse Biosciences to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios